Objective: To improve understanding of avian influenza in humans by presenting a case of avian influenza (H(5)N(1)).
Methods: Clinical and laboratory data of this case of avian influenza (H(5)N(1)) in humans were described, and related literature was reviewed.
Results: The female patient was 31 years old. She lived in epidemic district of avian influenza and had a history of close contact with sick poultry. The patient initially presented fever and chills accompanied by myalgia, and then followed by cough, blood-tinged sputum, dyspnea and frequent diarrhea. Laboratory findings indicated leukopenia, dysfunction of cellular immunity, abnormal enzymes of liver, and hypoxia. Patchy infiltration involved two lungs progressed rapidly on chest radiograph. ECG showed that T waves of V(1 - 5) were reverted. The patient was diagnosed with avian influenza (H(5)N(1)) by hemagglutination inhibition and microneutralization assay combined with epidemiological and clinical data. Supportive therapy, corticosteroids, antibacterial, and antiviral agents were administered. Complications were treated accordingly during the course. She got better overtime and recovered. The laboratory abnormalities and chest radiograph returned to normal before discharge. The patient's relatives and doctors involved in the medical care were free from infection.
Conclusions: Supportive treatment is important for patients with avian influenza. Complications should be prevented and treated in time.
Download full-text PDF |
Source |
---|
Front Microbiol
January 2025
College of Veterinary Medicine, Shanxi Agricultural University, Jinzhong, China.
Wild birds and waterfowl serve as the natural reservoirs of avian influenza viruses (AIVs). When AIVs originating from wild birds cross species barriers to infect mammals or humans, they pose a significant threat to public health. The H12 subtype of AIVs primarily circulates in wild birds, with relatively few isolates reported worldwide, and the evolutionary and biological characteristics of H12 subtype AIVs remain largely unknown.
View Article and Find Full Text PDFVirol Sin
January 2025
Zhejiang Provincial Center for Animal Disease Control and Prevention, Hangzhou 311199, China. Electronic address:
Cell
January 2025
Beijing Life Science Academy, Beijing 102200, China; CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences (CAS), Beijing 100101, China; National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China. Electronic address:
The ongoing circulation of highly pathogenic avian influenza (HPAI) A (H5N1) viruses, particularly clade 2.3.4.
View Article and Find Full Text PDFVet Microbiol
January 2025
Key Laboratory of Avian Bioproducts Development, College of Veterinary Medicine, Yangzhou University, Yangzhou, Jiangsu, China; Jiangsu Co-Innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonosis, College of Veterinary Medicine, Yangzhou University, Yangzhou, Jiangsu, China; Key Laboratory of Prevention and Control of Biological Hazard Factors (Animal Origin) for Agri-food Safety and Quality, Ministry of Agriculture of China (26116120), College of Veterinary Medicine, Yangzhou University, Yangzhou, Jiangsu, China.
Currently, there is increasing spillover of highly pathogenic H5N1 avian influenza virus (AIV) to mammals, raising a concern of pandemic threat about this virus. Although the function of PA protein of the influenza virus is well understood, the understanding of how phosphorylation regulates this protein and influenza viral life cycle is still limited. We previously identified PA S225 as the phosphorylation site in the highly pathogenic H5N1 AIV.
View Article and Find Full Text PDFAntibodies (Basel)
January 2025
Warwick Medical School, University of Warwick, Coventry CV4 7AL, UK.
Recent avian influenza outbreaks have heightened global concern over viral threats with the potential to significantly impact human health. Influenza is particularly alarming due to its history of causing pandemics and zoonotic reservoirs. In response, significant progress has been made toward the development of universal influenza vaccines, largely driven by the discovery of broadly neutralising antibodies (bnAbs), which have the potential to neutralise a broad range of influenza viruses, extending beyond the traditional strain-specific response.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!